Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

101.30 -1.25 (-1.22%)
Streaming Delayed Price Updated: 12:33 PM EDT, Oct 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,085,243
Open 102.24
Bid (Size) 101.29 (3)
Ask (Size) 101.31 (1)
Prev. Close 102.55
Today's Range 100.92 - 102.44
52wk Range 86.02 - 119.65
Shares Outstanding 2,531,374,696
Dividend Yield 2.57%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Steve Cohen Keeps Betting On Biopharma With Purchase Of 119M+ Bionomics Shares
NY Mets owner billionaire Steve Cohen has bought as many as 119,092,680 ordinary shares of clinical-stage biopharmaceutical company Bionomics Limited (NASDAQ: BNOX) through his Point72 asset management... 
Via Benzinga
Why Cancer-Focused ALX Oncology Stock Gained Over 100% Today?
ALX Oncology Holdings Inc (NASDAQ: ALXO) released prespecified interim Phase 2 data from its ASPEN-06 trial of evorpacept plus trastuzumab, Cyramza (ramucirumab) and paclitaxel for HER2-positive... 
Via Benzinga

Performance

YTD
-8.85%
-8.85%
1 Month
-5.78%
-5.78%
3 Month
-11.40%
-11.40%
6 Month
-6.95%
-6.95%
1 Year
+15.71%
+15.71%

More News

Read More
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
How Is The Market Feeling About Merck & Co?
Via Benzinga
These Market Experts See a Downturn Coming: 2 Defensive Index Funds That Are Proven Moneymakers to Buy Now
Via The Motley Fool
3 Reasons to Buy Merck Stock
Via The Motley Fool
Check Out What Whales Are Doing With MRK
Via Benzinga
Here's Why You Should Consider Moderna Stock, and No, It's Not the COVID Vaccine
Via The Motley Fool
Exposures COVID-19
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Amazon Web Services Now Offers Generative AI Tools For Businesses, Catches Up With Microsoft Azure, Google Cloud
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Pharma Giants Shift Stance, Embrace Medicare Negotiations Amid Rising Drug Costs
Via Benzinga
Merck Receives Priority Review from FDA for New Biologics License Application for Sotatercept, an Activin Signaling Inhibitor to Treat Adults with Pulmonary Arterial Hypertension (PAH)
From Merck & Co., Inc.
Via Business Wire
Mainz Biomed To Present The Power Of mRNA That Promises To Revolutionize Medicine
Via Benzinga
With Cancer Immunotherapy Market Set To Grow At Double-Digit CAGR Till 2032, This Company Plans To Ride The Wave Through Treatments For Complex Cancers
Via Benzinga
Why Is Seagen Stock Trading Higher Today?
Via Benzinga
Merck-Eisai Partnered Two Keytruda/Lenvima Combo Trials Flunk In Certain Types Of Lung Cancer
Via Benzinga
Seagen Pops After Scoring A 'Must-Win' For Its $43 Billion Takeover By Pfizer
Via Investor's Business Daily
Merck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer
From Merck & Co., Inc.
Via Business Wire
Merck Announces Phase 3 KEYNOTE-A39/EV-302 Trial Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
From Merck & Co., Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
On the Road to Halving Cancer: The 2023 Biotech Advancements Igniting Hope
Via FinancialNewsMedia
Flee to Healthcare Stocks if Recession Rears its Head?
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Concurrent Chemoradiotherapy as Treatment for Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
From Merck & Co., Inc.
Via Business Wire
FDA Accepts for Priority Review Merck’s Supplemental New Drug Application for WELIREG® (belzutifan) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
From Merck & Co., Inc.
Via Business Wire
Promising Preclinical Results From Blood Cancer Propel Oncternal To Buy Rating
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.